01—Abstract
Summary
Summary of the 10-K filed February 8, 2010. Cited figures are marked; the original filing is the authoritative source.
Neurocrine Biosciences, Inc. (NBIX) reported a net loss of $51.0 milliona, or $1.30 per share, for 2009, compared with $88.6 million, or $2.30 per share, in 2008.
Total revenues were $2.95 millionb in 2009, down from $3.98 million in 2008, and the company stated it has not generated any revenue from product sales. The company had an accumulated deficit of $754.3 million at December 31, 2009, and stockholders' equity of $3.95 million. Cash, cash equivalents and investments totaled $59.9 million at year-end 2009, down from $101.5 million at year-end 2008.
Management believes existing resources, investment income and future alliance payments will fund operations for at least the next 12 months, and states it does not expect to be profitable in 2010 or the foreseeable future. The company's lead program is elagolix, an oral GnRH antagonist for endometriosis, which is in Phase II. Management plans an end-of-Phase II meeting with the FDA in mid-2010 and states that elagolix Phase III trials will not begin until the program is partnered.
Other pipeline programs include a CRF1 antagonist being advanced by GlaxoSmithKline, urocortin 2 for heart failure, and a VMAT2 inhibitor in Phase I. Indiplon, the insomnia candidate, received a 2007 FDA approvable letter with new requirements, and the company ceased U.S. indiplon development activities and is evaluating alternatives. Funding relies on a $140 millionc shelf registration, a Committed Equity Financing Facility with Kingsbridge Capital of up to $75 million, and a December 2009 sale of about 4.8 million shares for $10.0 million gross.
Headcount was approximately 65 employees as of January 31, 2010, following a May 2009 restructuring. The filing also notes $20.4 milliond (par) of auction rate securities that remain illiquid.
02—Key points
Key Highlights
- Net loss narrowed to $51.0 million ($1.30 per share) in 2009 from $88.6 million ($2.30 per share) in 2008, with R&D expense falling to $35.8 million from $55.3 million.
- Total revenues were $2.95 million in 2009 versus $3.98 million in 2008; the company has not generated product sales revenue.
- Accumulated deficit reached $754.3 million and total stockholders' equity was $3.95 million at December 31, 2009.
- Cash, cash equivalents and investments were $59.9 million at year-end 2009, down from $101.5 million a year earlier; management expects existing resources to fund operations for at least 12 months.
- Lead program elagolix (endometriosis) is in Phase II; an end-of-Phase II FDA meeting is planned for mid-2010, with Phase III not expected to start until the program is partnered.
- Indiplon for insomnia received a 2007 FDA approvable letter with new requirements; U.S. development activities were ceased and alternatives are being evaluated.
- Financing sources include a $140 million shelf registration, a Kingsbridge Committed Equity Financing Facility of up to $75 million, and a December 2009 sale of about 4.8 million shares for $10.0 million gross.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-KFY2009filed February 8, 2010Financial Statements
| Revenue | $2.95M |
| R&D Expenses | $33.72M |
| Operating Expenses | $56.62M |
| Operating Income | -$53.67M |
| Net Income | -$51.04M |
| EPS (Basic) | $-1.30 |
| EPS (Diluted) | $-1.30 |
| Shares Outstanding (Basic) | 39.14M |
| Shares Outstanding (Diluted) | 39.14M |
05—Questions
Frequently Asked Questions
Is Neurocrine Biosciences generating revenue from product sales?
No. The filing states the company has not generated any revenues from the sale of products. Its 2009 revenues of $2.95 million came from collaboration milestones, license fees and sponsored research payments, primarily from Dainippon Sumitomo Pharma and GlaxoSmithKline.
Does the company expect to become profitable soon?
No. The filing states the company does not expect to be profitable for the year ending December 31, 2010 or for the foreseeable future, and it expects research and development and general and administrative expenses to decrease in 2010 due to cost savings efforts.
How is the company funding its operations?
Management says existing capital resources, investment income and future payments under strategic alliances should be sufficient for at least the next 12 months. The company also has a shelf registration for up to $140 million, a Kingsbridge CEFF for up to $75 million, and it sold about 4.8 million shares for $10.0 million gross in December 2009. Additional equity financings would be dilutive to stockholders.
What is the status of the company's lead drug candidate?
Elagolix, an oral GnRH antagonist for endometriosis, is in Phase II. The company plans an end-of-Phase II meeting with the FDA in mid-2010 to agree on the pivotal Phase III design, and expects to be ready for Phase III in late 2010, subject to FDA agreement. It does not intend to start Phase III until the program is partnered.
What risks are associated with the company's investment portfolio?
As of December 31, 2009, the company held $20.4 million (par value) of auction rate securities that are not liquid due to failed auctions. Their carrying value was $18.0 million. The company holds UBS ARS Rights allowing it to sell certain holdings to UBS at par, with an exercise period beginning June 30, 2010.
06—Continue